Free Trial

Reneo Pharmaceuticals Q1 2023 Earnings Report

Reneo Pharmaceuticals EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.63
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Reneo Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Reneo Pharmaceuticals Announcement Details

Quarter
Q1 2023
Time
N/A
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

Reneo Pharmaceuticals Earnings Headlines

Onkure Therapeutics Inc (OKUR)
Why I'm telling friends to avoid gold stocks
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
See More Reneo Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reneo Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reneo Pharmaceuticals and other key companies, straight to your email.

About Reneo Pharmaceuticals

Reneo Pharmaceuticals (NASDAQ:RPHM), a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

View Reneo Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings